- Home
- NLSP vs EDSA Comparison
NLSP vs EDSA Comparison
Compare NLSP & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLSP
- EDSA
- Stock Information
- Founded
- NLSP 2015
- EDSA 2015
- Country
- NLSP Switzerland
- EDSA Canada
- Employees
- NLSP N/A
- EDSA N/A
- Industry
- NLSP Biotechnology: Pharmaceutical Preparations
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- NLSP Health Care
- EDSA Health Care
- Exchange
- NLSP Nasdaq
- EDSA Nasdaq
- Market Cap
- NLSP 6.2M
- EDSA 6.2M
- IPO Year
- NLSP 2021
- EDSA N/A
- Fundamental
- Price
- NLSP $1.95
- EDSA $2.43
- Analyst Decision
- NLSP
- EDSA Strong Buy
- Analyst Count
- NLSP 0
- EDSA 1
- Target Price
- NLSP N/A
- EDSA $21.00
- AVG Volume (30 Days)
- NLSP 6.1M
- EDSA 5.9M
- Earning Date
- NLSP 10-18-2024
- EDSA 02-14-2025
- Dividend Yield
- NLSP N/A
- EDSA N/A
- EPS Growth
- NLSP N/A
- EDSA N/A
- EPS
- NLSP N/A
- EDSA N/A
- Revenue
- NLSP N/A
- EDSA N/A
- Revenue This Year
- NLSP N/A
- EDSA N/A
- Revenue Next Year
- NLSP N/A
- EDSA N/A
- P/E Ratio
- NLSP N/A
- EDSA N/A
- Revenue Growth
- NLSP N/A
- EDSA N/A
- 52 Week Low
- NLSP $1.71
- EDSA $1.55
- 52 Week High
- NLSP $18.40
- EDSA $5.59
- Technical
- Relative Strength Index (RSI)
- NLSP 44.06
- EDSA 56.54
- Support Level
- NLSP $2.14
- EDSA $2.30
- Resistance Level
- NLSP $2.34
- EDSA $4.49
- Average True Range (ATR)
- NLSP 0.24
- EDSA 0.30
- MACD
- NLSP -0.00
- EDSA 0.05
- Stochastic Oscillator
- NLSP 12.07
- EDSA 22.56
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.